Clinical relevance of semaphorin-3F in patients with prostate cancer

Clin Invest Med. 2019 Sep 29;42(3):E64-E69. doi: 10.25011/cim.v42i3.33094.

Abstract

Purpose: To identify prognosis predictors for patients with prostate cancer (PCa).

Methods: Four independent PCa microarray datasets (GSE32448, GSE16560, GSE79957 and GSE17951) were reanalyzed to characterize the expression of semaphorin-3F (SEMA3F) gene between PCa patients and normal prostate tissues and the correlation between SEMA3F expression and the age, tumor/nodes/metastasis (TNM) staging, Gleason Grade Group, prostate-specific antigen level and overall survival of PCa patients. Gene set enrichment analysis was applied to investigate the potential relevant mechanisms regarding the expression of SEMA3F and the proliferation of PCa cells.

Results: The level of SEMA3F was significantly higher in normal prostate tissues compared with that in PCa cells (P.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cell Line, Tumor
  • Databases, Nucleic Acid
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • Membrane Proteins / biosynthesis*
  • Membrane Proteins / genetics
  • Middle Aged
  • Neoplasm Staging
  • Nerve Tissue Proteins / biosynthesis*
  • Nerve Tissue Proteins / genetics
  • Oligonucleotide Array Sequence Analysis*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Tumor Suppressor Proteins / biosynthesis*
  • Tumor Suppressor Proteins / genetics

Substances

  • Membrane Proteins
  • Nerve Tissue Proteins
  • SEMA3F protein, human
  • Tumor Suppressor Proteins